Effects of downhill walking in pulmonary rehabilitation for patients with COPD: a randomised controlled trial.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
16
09
2019
accepted:
26
04
2020
pubmed:
24
5
2020
medline:
22
6
2021
entrez:
24
5
2020
Statut:
epublish
Résumé
The development of contractile muscle fatigue (CMF) affects training responses in patients with chronic obstructive pulmonary disease (COPD). Downhill walking induces CMF with lower dyspnoea and fatigue than level walking. This study compared the effect of pulmonary rehabilitation (PR) comprising downhill walking training (DT) to PR comprising level walking (conventional training (CT)) in patients with COPD.In this randomised controlled trial, 35 patients (62±8 years; forced expiratory volume in 1 s (FEV
Identifiants
pubmed: 32444407
pii: 13993003.00639-2020
doi: 10.1183/13993003.00639-2020
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02113748']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: C.A. Camillo has nothing to disclose. Conflict of interest: C.R. Osadnik has nothing to disclose. Conflict of interest: C. Burtin has nothing to disclose. Conflict of interest: S. Everaerts has nothing to disclose. Conflict of interest: M. Hornikx has nothing to disclose. Conflict of interest: H. Demeyer has nothing to disclose. Conflict of interest: M. Loeckx has nothing to disclose. Conflict of interest: F.M. Rodrigues has nothing to disclose. Conflict of interest: K. Maes has nothing to disclose. Conflict of interest: G. Gayan-Ramirez has nothing to disclose. Conflict of interest: W. Janssens reports grants and personal fees from Boehringer Ingelheim, AstraZeneca, GSK and Chiesi, outside the submitted work; and is senior clinical researcher of FWO co-founder of ArtiQ. Conflict of interest: T. Troosters has nothing to disclose.